We've had a lot of conversations with federal government scientists and regulators on their viewpoints. I actually gave a presentation to Health Canada last month on the new approaches. I think the Canadian scientific community, even in these government regulatory programs, is very much aware of the new science and is accepting of it.
It has been amazing how much endorsement we have from around the world, not just computational methods but high-throughput in vitro screens, high-throughput pharmacokinetics, and high-throughput exposomics. It's a total revolution, and I think the future is really offering us a huge opportunity to do things we never could in the past, and maybe give Lynda the data that she'll be able to use for risk assessment without having to fall back on the precautionary principle.